BALAXI PHARMACEUTICALS LIMITED has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
BALAXI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Balaxi Pharmaceuticals Limited has filed a disclosure under SEBI Regulation 31(4) for the financial year ended March 31, 2026. Ashish Maheshwari, Director of Balaxi Overseas Private Limited (a promoter entity), has declared on behalf of the Promoter and Promoter Group along with persons acting in concert that no encumbrance (share pledging) was made, directly or indirectly, during the financial year. This is a routine regulatory filing to maintain transparency about promoter shareholding patterns.
Positive signal for investors as it confirms promoters have not pledged their shares during the year, indicating no risk of forced share sales and demonstrating promoter confidence in the company.